ReviewCurrent neurology and neuroscience reports2019
Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.Neurology · 2025Article
- Post-traumatic myelin oligodendrocyte glycoprotein antibody optic neuritis: A case report.American journal of ophthalmology case reports · 2025Article
- Advances in biomarkers for optic neuritis and neuromyelitis optica spectrum disorders: a multi-omics perspective.Frontiers in neurology · 2025Review
- A case of post-infectious anti-myelin oligodendrocyte glycoprotein antibody-positive optic neuritis.International journal of ophthalmology · 2025Article
- In Silico Modeling of Myelin Oligodendrocyte Glycoprotein Disulfide Bond Reduction by Phosphine-Borane Complexes.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Optic Neuritis Leading to Vision Loss: A Case of MOG-Associated Disease with Successful Immunotherapy.The American journal of case reports · 2024Article
- Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Optic Neuritis - A Case Report and Literature Review.International medical case reports journal · 2024Article
- Neuromyelitis Optica: Pathogenesis Overlap with Other Autoimmune Diseases.Current allergy and asthma reports · 2023Review
- Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.Journal of neurology · 2023Review
- Pregnancy prevalence and outcomes after optic neuritis in South Korea.Scientific reports · 2023Article
- Details and outcomes of a large cohort of MOG-IgG associated optic neuritis.Multiple sclerosis and related disorders · 2022Article
- Structure-function correlates of vision loss in neuromyelitis optica spectrum disorders.Scientific reports · 2022Article
- Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.Journal of neurology · 2022Observational
- Multidisciplinary Rehabilitation for Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Case Report.Brain & NeuroRehabilitation · 2022Article
- OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS.Multiple sclerosis and related disorders · 2022Article
- Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.Acta neurologica Belgica · 2022Article
- Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?Frontiers in neurology · 2022Review
- Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies.International journal of ophthalmology · 2022Article
- GAP-43 Induces the Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Retinal Ganglial-Like Cells.Computational and mathematical methods in medicine · 2022Article
- Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAntibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with a unique acquired central nervous system demyelinating disease-termed MOG-IgG-associated disorder (MOGAD)-which has a variety of clinical manifestations, including optic neuritis, transverse myelitis, acute disseminating encephalomyelitis, and brainstem encephalitis. In this review, we summarize the current knowledge of the clinical characteristics, neuroimaging, treatments, and outcomes of MOGAD, with a focus on optic neuritis. RECENT
findingsThe recent development of a reproducible, live cell-based assay for MOG-IgG, has improved our ability to identify and study this disease. Based on contemporary studies, it has become increasingly evident that MOGAD is distinct from multiple sclerosis and aquaporin-4-positive neuromyelitis optica spectrum disorder with different clinical features and treatment outcomes. There is now sufficient evidence to separate MOGAD from other inflammatory central nervous system demyelinating disorders, which will allow focused research on understanding the pathophysiology of the disease. Prospective treatment trials are needed to determine the best course of treatment, and until then, treatment plans must be individualized to the clinical manifestations and severity of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.